| Tackling antibiotic resistance K Bush, P Courvalin, G Dantas, J Davies, B Eisenstein, P Huovinen, ... Nature Reviews Microbiology 9 (12), 894, 2011 | 1265 | 2011 |
| Phage treatment of human infections ST Abedon, SJ Kuhl, BG Blasdel, EM Kutter Bacteriophage 1 (2), 66-85, 2011 | 1149 | 2011 |
| Bacteriophage T4 genome ES Miller, E Kutter, G Mosig, F Arisaka, T Kunisawa, W Rüger Microbiology and molecular biology reviews 67 (1), 86-156, 2003 | 907 | 2003 |
| Bacteriophages: biology and applications E Kutter, A Sulakvelidze CRC Press, 2004 | 873 | 2004 |
| Phage therapy in clinical practice: treatment of human infections E Kutter, D De Vos, G Gvasalia, Z Alavidze, L Gogokhia, S Kuhl, ... Current pharmaceutical biotechnology 11 (1), 69-86, 2010 | 854 | 2010 |
| Phage host range and efficiency of plating E Kutter Bacteriophages, 141-149, 2009 | 514 | 2009 |
| A Restriction Map of the Bacteriophage T4 Genome H O’Farrell Patrick, K Elizabeth, N Mikiye Mol Gen Genet 179 (2), 421-435, 2010 | 368* | 2010 |
| A restriction map of the bacteriophage T4 genome PH O'Farrell, E Kutter, M Nakanishi Molecular and General Genetics MGG 179 (2), 421-435, 1980 | 368 | 1980 |
| In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy S Chibani-Chennoufi, J Sidoti, A Bruttin, E Kutter, S Sarker, H Brüssow Antimicrobial agents and chemotherapy 48 (7), 2558-2569, 2004 | 356 | 2004 |
| Bacteriophage therapy in humans E Kutter Bacteriophages, Biology and Applications, 381-436, 2005 | 318* | 2005 |
| Basic phage biology B Guttman, R Raya, E Kutter Bacteriophages: Biology and applications 4, 2005 | 311 | 2005 |
| 14 Bacteriophage Therapy in Humans A Sulakvelidze, E Kutter Bacteriophages: biology and applications, 381, 2004 | 305 | 2004 |
| Quality and safety requirements for sustainable phage therapy products JP Pirnay, BG Blasdel, L Bretaudeau, A Buckling, N Chanishvili, JR Clark, ... Pharmaceutical research 32 (7), 2173-2179, 2015 | 249 | 2015 |
| Isolation and characterization of a new T-even bacteriophage, CEV1, and determination of its potential to reduce Escherichia coli O157: H7 levels in sheep RR Raya, P Varey, RA Oot, MR Dyen, TR Callaway, TS Edrington, ... Applied and environmental microbiology 72 (9), 6405-6410, 2006 | 219 | 2006 |
| Bacteriophage treatment of intransigent diabetic toe ulcers: a case series R Fish, E Kutter, G Wheat, B Blasdel, M Kutateladze, S Kuhl Journal of wound care 25 (Sup7), S27-S33, 2016 | 217 | 2016 |
| Bacteriophage Isolated from Feedlot Cattle Can Reduce Escherichia coli O157:H7 Populations in Ruminant Gastrointestinal Tracts TR Callaway, TS Edrington, AD Brabban, RC Anderson, ML Rossman, ... Foodborne Pathogens and Disease 5 (2), 183-191, 2008 | 185 | 2008 |
| Degradation of cytosine-containing bacterial and bacteriophage DNA after infection of Escherichia coli B with bacteriophage T4D wild type and with mutants defective in genes 46 … EM Kutter, JS Wiberg Journal of molecular biology 38 (3), 395-411, 1968 | 180 | 1968 |
| Evaluation of lytic activity of staphylococcal bacteriophage Sb‐1 against freshly isolated clinical pathogens L Kvachadze, N Balarjishvili, T Meskhi, E Tevdoradze, N Skhirtladze, ... Microbial biotechnology 4 (5), 643-650, 2011 | 171 | 2011 |
| Bacteriophage T4 infection of stationary phase E. coli: life after log from a phage perspective D Bryan, A El-Shibiny, Z Hobbs, J Porter, EM Kutter Frontiers in microbiology 7, 1391, 2016 | 170 | 2016 |
| Re-establishing a place for phage therapy in western medicine EM Kutter, SJ Kuhl, ST Abedon Future microbiology 10 (5), 685-688, 2015 | 142 | 2015 |
